Wael A Harb MD

Oncology•Newport Beach, CA

Founder of Horizon Oncology Center

Join to View Full Profile

1441 Avocado AveSte 301Newport Beach, CA 92660
Phone+1 949-272-2095
Fax+1 949-272-2096

Education & Training

Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 1996 - 1998
Indiana University School of MedicineResidency, Internal Medicine, 1993 - 1996
Damascus University Faculty of MedicineClass of 1992

Certifications & Licensure

CA State Medical License 2021 - 2025
MI State Medical License 2018 - 2023
IN State Medical License 1996 - 2021
American Board of Internal Medicine Medical Oncology

Clinical Trials

Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer Start of enrollment: 2008 Jan 01
Completed
Phase 2
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
COMPLETED
PHASE1, PHASE2
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
COMPLETED
PHASE2
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma Start of enrollment: 2011 Feb 09
Completed
Phase 2
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors Start of enrollment: 2011 Oct 01
Completed
Phase 1
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment Start of enrollment: 2012 Jan 01
Completed
Phase 1
Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2012 Nov 01
Completed
Phase 2
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer Start of enrollment: 2013 Sep 06
Completed
Phase 1
ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma Start of enrollment: 2014 Mar 01
TERMINATED
PHASE1, PHASE2
Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors Start of enrollment: 2013 Oct 01
Completed
Phase 1
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer Start of enrollment: 2014 Mar 05
Completed
Phase 1
Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. Start of enrollment: 2014 Jun 27
Completed
Phase 1
A Phase 2 Study of CPI-0610 with and Without Ruxolitinib in Patients with Myelofibrosis Start of enrollment: 2014 Jul 16
COMPLETED
PHASE1, PHASE2
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Start of enrollment: 2014 Sep 09
Terminated
Phase 2
A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer Start of enrollment: 2015 Apr 15
Completed
Phase 1, Phase 2
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC Start of enrollment: 2017 Jun 29
Terminated
Phase 2
Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors Start of enrollment: 2017 Nov 28
Active, not recruiting
Phase 1
Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma Start of enrollment: 2019 Apr 16
COMPLETED
PHASE1
Join now to see all

Publications & Presentations

PubMed

4 citations
Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies.
Eytan M Stein, Amir T Fathi, Wael A Harb, Gozde Colak, Andrea Fusco
Leukemia & Lymphoma. 2024-04-01
13 citations
First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors.
Devalingam Mahalingam, Wael Harb, Amita Patnaik, Andrea Bullock, Randolph S Watnick
Communications Medicine. 2024-01-13
16 citations
Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I ...
Marwan Fakih, Wael Harb, Daruka Mahadevan, Hani Babiker, Jordan Berlin
Journal for Immunotherapy of Cancer. 2023-04-01

Press Mentions

Certain Type of Statins May Help Decrease Liver Cancer RiskMarch 26th, 2025
Mediterranean Diet Could Help Lower Cancer Risk in ObesityMarch 2nd, 2025
2 Out of 25 Lifestyle and Environmental Factors Affect Aging the Most, Study FindsFebruary 24th, 2025
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member